What is the recommended dosing regimen for Engerix-B (hepatitis B vaccine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Engerix-B Dosing Recommendations

Standard Adult Dosing (≥20 years)

For adults aged 20 years and older, administer Engerix-B 20 μg (1.0 mL) intramuscularly at 0,1, and 6 months. 1, 2

  • This 3-dose schedule achieves >90% seroprotection rates in adults under 40 years of age 1
  • The vaccine should be administered in the deltoid muscle 2
  • Shake the vial well before administration; the vaccine should appear as a slightly turbid white suspension 2

Adolescent Dosing (11-19 years)

Adolescents aged 11-19 years should receive Engerix-B 10 μg (0.5 mL) at 0,1, and 6 months. 1, 2

  • An alternative 2-dose regimen using the adult formulation (20 μg) at 0 and 6 months is also acceptable for adolescents aged 11-15 years 1, 3
  • The 2-dose regimen achieves 96.7% seroprotection, which is non-inferior to the standard 3-dose schedule 3

Pediatric Dosing (Birth through 10 years)

Children from birth through age 10 should receive Engerix-B 10 μg (0.5 mL) at 0,1, and 6 months. 1, 2

  • For infants born to HBsAg-positive mothers, the first dose must be given within 12 hours of birth along with HBIG 4, 2
  • The final dose must not be administered before 24 weeks of age 4

Hemodialysis and Immunocompromised Patients (≥20 years)

Adults on hemodialysis or who are immunocompromised require Engerix-B 40 μg (2.0 mL) administered as either a single 2-mL injection or two 1-mL injections at 0,1,2, and 6 months (4-dose series). 1, 2

  • Annual anti-HBs testing is mandatory for hemodialysis patients 2
  • Administer a 40 μg booster dose when antibody levels fall below 10 mIU/mL 2
  • Do not use Heplisav-B or PreHevbrio in hemodialysis patients, as safety and efficacy have not been established 1

Alternative Accelerated Schedules

For rapid protection in high-risk situations (recent exposure, travelers), use the accelerated 4-dose schedule: 0,1,2, and 12 months. 1, 2

  • This schedule is designed for neonates born to HBV-infected mothers, recently exposed individuals, and certain travelers to high-risk areas 2
  • The additional dose at 12 months is recommended for prolonged maintenance of protective titers 2

Critical Minimum Intervals

If the vaccination series is interrupted, do not restart—simply continue where you left off. 1, 4

  • Minimum interval between doses 1 and 2: 4 weeks 1
  • Minimum interval between doses 2 and 3: 8 weeks 1
  • Minimum interval between doses 1 and 3: 16 weeks 1
  • Doses administered ≤4 days before the minimum interval are considered valid 1, 4

Special Population Considerations

Pregnant Women

Pregnant women requiring hepatitis B vaccination should receive Engerix-B, Recombivax HB, or Twinrix only. 1

  • Do not use Heplisav-B or PreHevbrio in pregnancy due to insufficient safety data 1

Older Adults

Vaccine response declines with age; adults over 40 years have lower seroconversion rates than younger adults. 1

  • Consider post-vaccination serologic testing 1-2 months after series completion in older adults to document response 5
  • For documented non-responders, consider revaccination with Heplisav-B (90% seroprotection) or a high-dose Engerix-B series (40 μg at 0,1,2, and 6 months) 5

Common Pitfalls to Avoid

  • Never restart the series if interrupted—this wastes doses and delays protection 1, 4
  • Never administer the third dose before 16 weeks from the first dose, even if 8 weeks have passed since the second dose 1
  • Never use standard adult doses (20 μg) in hemodialysis patients—they require 40 μg doses 1, 2
  • Never administer subcutaneously unless the patient has a bleeding disorder—this results in lower antibody titers and increased local reactions 2
  • Never use Heplisav-B or PreHevbrio in pregnant women, children, or hemodialysis patients 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hepatitis B Vaccination Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Hepatitis B Vaccine Non-Response

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.